Clinical Trials
AdvanCell’s Lead-212 Radioligand Therapy Shows Strong Safety and Efficacy in Phase 1b Trial for Metastatic Prostate Cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastat...
October 22, 2025 | News
Thermo Fisher’s PPD Business Launches Carbon Calculator to Drive Sustainable Clinical Research
New tool helps sponsors measure, manage and minimize the environmental impact of research The PPD™ clinical research business of Thermo Fisher Scien...
October 22, 2025 | News
Sanofi’s Efluelda (Fluzone High-Dose) Cuts Influenza Hospitalisations by 31.9% in Adults Aged 65+
Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by a...
October 21, 2025 | News
Sichuan Kelun-Biotech’s Trastuzumab Botidotin Approved in China for HER2-Positive Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor recep...
October 20, 2025 | News
Ascletis Completes U.S. Phase IIa Enrollment for Once-Monthly ASC30 GLP-1 Depot Therapy in Obesity
The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) d...
October 20, 2025 | News
Aurion Biotech Data Supports Advancing High-Dose AURN001 Regenerative Cell Therapy to Phase 3 Trial in 2026
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1...
October 20, 2025 | News
Daiichi Sankyo and AstraZeneca’s DATROWAY Combination Delivers 68.2% Response and 95.5% Disease Control in First-Line Metastatic Urothelial Cancer
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in c...
October 20, 2025 | News
Merck Presents Longer-Term Phase 3 Data Showing Pimicotinib Achieves 76.2% Objective Response Rate in TGCT
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2% Global Phase 3 MANEUVER study de...
October 20, 2025 | News
PeptiDream, PDRadiopharma, and Curium Launch Registrational Phase 2 Trial in Japan for 64Cu-PSMA-I&T Targeting Prostate Cancer
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...
October 17, 2025 | News
Jacobio Pharma Partners with Oceanpine Capital in RMB 200 Million Equity Deal for Cardiovascular Research Subsidiary
Jacobio Pharma announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity...
October 16, 2025 | News
SK Bioscience Files Clinical Trial Application in Australia for GBP511 Universal Coronavirus Vaccine
Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses Phase 1/2 study to enroll ~500 healthy adults, with topline results e...
October 16, 2025 | News
Ascletis’ Denifanstat (ASC40) Achieves Phase III Success in Moderate-to-Severe Acne Vulgaris
Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulga...
October 15, 2025 | News
Clover Biopharmaceuticals Reports Promising Phase I Results for RSV+hMPV±PIV3 Combination Vaccines
Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously...
October 15, 2025 | News
Ascletis Selects ASC35 as Once-Monthly, Dual GLP-1/GIP Peptide Agonist Candidate for Obesity Treatment
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, whic...
October 14, 2025 | News
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
